Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
1982
713
LTM Revenue $62.6M
LTM EBITDA $17.2M
$139M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, Kotra Industries reported last 12-month revenue of $62.6M and EBITDA of $17.2M.
In the same period, Kotra Industries achieved $11.2M in LTM net income.
See Kotra Industries valuation multiples based on analyst estimatesIn the most recent fiscal year, Kotra Industries reported revenue of $57.0M and EBITDA of $16.0M.
Kotra Industries expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Kotra Industries valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $62.6M | XXX | $57.0M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $42.0M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $17.2M | XXX | $16.0M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $12.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $11.2M | XXX | $10.5M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kotra Industries has current market cap of MYR 616M (or $152M), and EV of MYR 564M (or $139M).
As of January 2, 2026, Kotra Industries's stock price is MYR 4 (or $1).
See Kotra Industries trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $139M | $152M | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialKotra Industries's trades at 2.2x EV/Revenue multiple, and 7.9x EV/EBITDA.
See valuation multiples for Kotra Industries and 15K+ public compsAs of January 2, 2026, Kotra Industries has market cap of $152M and EV of $139M.
Equity research analysts estimate Kotra Industries's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kotra Industries has a P/E ratio of 13.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $152M | XXX | $152M | XXX | XXX | XXX |
| EV (current) | $139M | XXX | $139M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 11.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.6x | XXX | 13.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 30.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKotra Industries's last 12 month revenue growth is 10%
Kotra Industries's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $42K for the same period.
Kotra Industries's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kotra Industries's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kotra Industries and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $42K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kotra Industries acquired XXX companies to date.
Last acquisition by Kotra Industries was XXXXXXXX, XXXXX XXXXX XXXXXX . Kotra Industries acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Kotra Industries founded? | Kotra Industries was founded in 1982. |
| Where is Kotra Industries headquartered? | Kotra Industries is headquartered in Malaysia. |
| How many employees does Kotra Industries have? | As of today, Kotra Industries has 713 employees. |
| Is Kotra Industries publicy listed? | Yes, Kotra Industries is a public company listed on KLS. |
| What is the stock symbol of Kotra Industries? | Kotra Industries trades under 0002 ticker. |
| When did Kotra Industries go public? | Kotra Industries went public in 2002. |
| Who are competitors of Kotra Industries? | Similar companies to Kotra Industries include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kotra Industries? | Kotra Industries's current market cap is $152M |
| What is the current revenue of Kotra Industries? | Kotra Industries's last 12 months revenue is $62.6M. |
| What is the current revenue growth of Kotra Industries? | Kotra Industries revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Kotra Industries? | Current revenue multiple of Kotra Industries is 2.2x. |
| Is Kotra Industries profitable? | Yes, Kotra Industries is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kotra Industries? | Kotra Industries's last 12 months EBITDA is $17.2M. |
| What is Kotra Industries's EBITDA margin? | Kotra Industries's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Kotra Industries? | Current EBITDA multiple of Kotra Industries is 8.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.